New York Judge Grants Summary Judgment for Bayer in Mirena IUD Litigation
Roughly 8.5 percent of women in the United States use long-term birth control devices like intrauterine devices or IUDs. This method offers up to five years of birth control by emitting low-dose hormones. The implant can be removed at any time if the woman decides that she no longer wants to use the device or decides that she would like to become pregnant.
Despite the purported benefits of many IUD devices, some of them cause serious injuries and painful consequences for patients. One example is Bayer, which manufactured an IUD device marketed and sold under the brand name Mirena. The Mirena IUD was approved in Europe in 1991 and was approved by the U.S. Food and Drug Administration in 2000. Since its approval, the FDA has received over 45,000 reports of adverse events associated with Mirena IUD devices, including expulsion, migration, dislocation, and hemorrhaging of the vagina.
In the ensuing litigation and multitude of lawsuits filed against Bayer, patients alleged that Bayer intentionally sold the product despite knowing of the dangerous, painful, and life-threatening complications that could arise. The lawsuits were eventually consolidated into an MDL proceeding, which stands for multi-district litigation. Like a class action, common legal issues and factual issues are decided at the global level. When it comes to individual damages, however, each plaintiff must still prove his or her case before being awarded any compensation.